Literature DB >> 9279764

Phenotypic expression of the fibroblast growth factor receptor 3 (FGFR3) mutation P250R in a large craniosynostosis family.

A Golla1, P Lichmer, S von Gernet, A Winterpacht, J Fairley, J Murken, S Schuffenhauer.   

Abstract

The craniosynostosis syndromes are a heterogeneous group of sporadic, autosomal dominant disorders with significant clinical overlap. Recently, we described a large family with autosomal dominant craniosynostosis suggestive of Saethre-Chotzen syndrome, in which linkage to the Saethre-Chotzen syndrome loci on 7p had been excluded. We now report the presence of a mutation in the fibroblast growth factor receptor 3 (FGFR3) in this family. The mutation, P250R, had been previously reported in 10 patients with non-syndromic craniosynostosis. Variable expression of this mutation is evident especially in two additional members of this family, one of whom is severely affected with pancraniosynostosis. The family provides a further example of genetic heterogeneity and variable expression of the craniosynostosis syndromes and broadens the phenotypic spectrum associated with the FGFR3 mutation P250R. In addition, we found a polymorphism (F384L) in the transmembrane domain of FGFR3 which occurs with a frequency of 3% in the Turkish population but is uncommon among Germans.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9279764      PMCID: PMC1051034          DOI: 10.1136/jmg.34.8.683

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  13 in total

1.  Basic local alignment search tool.

Authors:  S F Altschul; W Gish; W Miller; E W Myers; D J Lipman
Journal:  J Mol Biol       Date:  1990-10-05       Impact factor: 5.469

2.  FGFR2 mutations in Pfeiffer syndrome.

Authors:  E Lajeunie; H W Ma; J Bonaventure; A Munnich; M Le Merrer; D Renier
Journal:  Nat Genet       Date:  1995-02       Impact factor: 38.330

3.  A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome.

Authors:  M Muenke; U Schell; A Hehr; N H Robin; H W Losken; A Schinzel; L J Pulleyn; P Rutland; W Reardon; S Malcolm
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

4.  Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes.

Authors:  G A Bellus; K Gaudenz; E H Zackai; L A Clarke; J Szabo; C A Francomano; M Muenke
Journal:  Nat Genet       Date:  1996-10       Impact factor: 38.330

5.  Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome.

Authors:  A O Wilkie; S F Slaney; M Oldridge; M D Poole; G J Ashworth; A D Hockley; R D Hayward; D J David; L J Pulleyn; P Rutland
Journal:  Nat Genet       Date:  1995-02       Impact factor: 38.330

6.  Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia.

Authors:  R Shiang; L M Thompson; Y Z Zhu; D M Church; T J Fielder; M Bocian; S T Winokur; J J Wasmuth
Journal:  Cell       Date:  1994-07-29       Impact factor: 41.582

7.  Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome.

Authors:  W Reardon; R M Winter; P Rutland; L J Pulleyn; B M Jones; S Malcolm
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

8.  Mutations in FGFR1 and FGFR2 cause familial and sporadic Pfeiffer syndrome.

Authors:  U Schell; A Hehr; G J Feldman; N H Robin; E H Zackai; C de Die-Smulders; D H Viskochil; J M Stewart; G Wolff; H Ohashi
Journal:  Hum Mol Genet       Date:  1995-03       Impact factor: 6.150

9.  A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia.

Authors:  G A Bellus; I McIntosh; E A Smith; A S Aylsworth; I Kaitila; W A Horton; G A Greenhaw; J T Hecht; C A Francomano
Journal:  Nat Genet       Date:  1995-07       Impact factor: 38.330

10.  Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.

Authors:  P L Tavormina; R Shiang; L M Thompson; Y Z Zhu; D J Wilkin; R S Lachman; W R Wilcox; D L Rimoin; D H Cohn; J J Wasmuth
Journal:  Nat Genet       Date:  1995-03       Impact factor: 38.330

View more
  7 in total

1.  Medical treatment of craniosynostosis: recombinant Noggin inhibits coronal suture closure in the rat craniosynostosis model.

Authors:  K Shen; S M Krakora; M Cunningham; M Singh; X Wang; F Z Hu; J C Post; G D Ehrlich
Journal:  Orthod Craniofac Res       Date:  2009-08       Impact factor: 1.826

2.  Morphometric analysis of untreated adult skulls in syndromic and nonsyndromic craniosynostosis.

Authors:  J Weber; H Collmann; A Czarnetzki; A Spring; C M Pusch
Journal:  Neurosurg Rev       Date:  2007-11-09       Impact factor: 3.042

3.  Sex related expressivity of the phenotype in coronal craniosynostosis caused by the recurrent P250R FGFR3 mutation.

Authors:  E Lajeunie; V El Ghouzzi; M Le Merrer; A Munnich; J Bonaventure; D Renier
Journal:  J Med Genet       Date:  1999-01       Impact factor: 6.318

4.  FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.

Authors:  Sumin Kang; Shaozhong Dong; Ting-Lei Gu; Ailan Guo; Michael S Cohen; Sagar Lonial; Hanna Jean Khoury; Doriano Fabbro; D Gary Gilliland; P Leif Bergsagel; Jack Taunton; Roberto D Polakiewicz; Jing Chen
Journal:  Cancer Cell       Date:  2007-09       Impact factor: 31.743

5.  Muenke syndrome.

Authors:  G Sabatino; F Di Rocco; G Zampino; G Tamburrini; M Caldarelli; C Di Rocco
Journal:  Childs Nerv Syst       Date:  2004-02-10       Impact factor: 1.475

6.  Frequency of the allelic variant c.1150T > C in exon 10 of the fibroblast growth factor receptor 3 (FGFR3) gene is not increased in patients with pathogenic mutations and related chondrodysplasia phenotypes.

Authors:  Thatiane Yoshie Kanazawa; Luciana Cardoso Bonadia; Denise Pontes Cavalcanti
Journal:  Genet Mol Biol       Date:  2014-10-21       Impact factor: 1.771

Review 7.  The Fibroblast Growth Factor signaling pathway.

Authors:  David M Ornitz; Nobuyuki Itoh
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-03-13       Impact factor: 5.814

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.